Free Trial
NASDAQ:SPRY

ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

ARS Pharmaceuticals logo
$17.18 -0.50 (-2.83%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$17.32 +0.14 (+0.79%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About ARS Pharmaceuticals Stock (NASDAQ:SPRY)

Key Stats

Today's Range
$17.07
$17.70
50-Day Range
$13.44
$18.35
52-Week Range
$8.91
$18.90
Volume
1.18 million shs
Average Volume
1.21 million shs
Market Capitalization
$1.69 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00
Consensus Rating
Buy

Company Overview

ARS Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
64th Percentile Overall Score

SPRY MarketRank™: 

ARS Pharmaceuticals scored higher than 64% of companies evaluated by MarketBeat, and ranked 412th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    ARS Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about ARS Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ARS Pharmaceuticals is -107.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ARS Pharmaceuticals is -107.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    ARS Pharmaceuticals has a P/B Ratio of 6.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ARS Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    26.75% of the float of ARS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ARS Pharmaceuticals has recently decreased by 5.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ARS Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    ARS Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    26.75% of the float of ARS Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    ARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in ARS Pharmaceuticals has recently decreased by 5.89%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ARS Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for ARS Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    6 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,024,863.00 in company stock.

  • Percentage Held by Insiders

    33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ARS Pharmaceuticals' insider trading history.
Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SPRY Stock News Headlines

China just unlocked Nvidia’s AI chips—what that means for you
Tired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system tracks breaking AI news and shows when to trade.📈 AI-backed. Beginner-friendly. Results proven.
ARS Pharmaceuticals: 'Betting On The Come'
See More Headlines

SPRY Stock Analysis - Frequently Asked Questions

ARS Pharmaceuticals' stock was trading at $10.55 at the beginning of 2025. Since then, SPRY shares have increased by 62.8% and is now trading at $17.18.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The business earned $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. ARS Pharmaceuticals had a negative net margin of 16.11% and a negative trailing twelve-month return on equity of 6.94%.
Read the conference call transcript
.

Top institutional investors of ARS Pharmaceuticals include Aberdeen Group plc (1.53%), Janney Montgomery Scott LLC (0.60%), Peregrine Capital Management LLC (0.47%) and Allspring Global Investments Holdings LLC (0.30%). Insiders that own company stock include Ra Capital Management, LP, Richard E Lowenthal, Sarina Tanimoto, Laura Shawver, Justin Chakma, Alexander A Fitzpatrick, Eric Karas, Kathleen D Scott, Brian Dorsey, Peter A Thompson and Brent L Saunders.
View institutional ownership trends
.

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/14/2025
Today
8/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRY
CIK
1671858
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

High Price Target
$40.00
Low Price Target
$27.00
Potential Upside/Downside
+80.4%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.16)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$8 million
Net Margins
-16.11%
Pretax Margin
-15.82%
Return on Equity
-6.94%
Return on Assets
-5.60%

Debt

Debt-to-Equity Ratio
0.30
Current Ratio
11.00
Quick Ratio
10.74

Sales & Book Value

Annual Sales
$97.12 million
Price / Sales
17.37
Cash Flow
$0.01 per share
Price / Cash Flow
2,087.79
Book Value
$2.64 per share
Price / Book
6.51

Miscellaneous

Outstanding Shares
98,214,000
Free Float
65,312,000
Market Cap
$1.69 billion
Optionable
Optionable
Beta
0.90

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:SPRY) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners